Silo Pharma (NASDAQ: SILO) has entered into a service agreement with Resyca BV to conduct a critical drug-device study on its microchip-enabled nasal spray system, a key component of its lead PTSD treatment candidate, SPC-15. This study aims to gather the necessary device data for an Investigational New Drug (IND) application to the FDA, anticipated later this year. The innovative nasal spray system is designed to bypass the blood-brain barrier, a feature that CEO Eric Weisblum suggests could enable quicker and more secure delivery of therapeutics.
In addition to this study, Silo Pharma is making progress with two other SPC-15 studies. These include a GLP-compliant toxicology study and a 7-day large animal safety trial, the latter of which was specifically requested by the FDA. These developments underscore Silo Pharma's commitment to addressing underserved conditions such as stress-induced psychiatric disorders through novel formulations and drug-delivery systems.
Silo Pharma's pipeline also includes SP-26, a time-release, ketamine-loaded implant aimed at providing relief for fibromyalgia and chronic pain, and two preclinical programs: SPC-14, targeting Alzheimer’s disease, and SPU-16, focused on multiple sclerosis. The company's approach to research and development, which involves collaborations with universities and independent laboratories, reflects a broader trend in the biopharmaceutical industry toward leveraging external expertise to accelerate innovation.
The implications of Silo Pharma's advancements extend beyond the immediate potential for new treatments. The successful development and approval of SPC-15 could set a precedent for the use of psychedelic treatments in novel formulations, offering hope to millions suffering from PTSD and stress-induced anxiety disorders. Furthermore, the company's focus on innovative drug-delivery systems, such as the microchip-enabled nasal spray, highlights the growing importance of technology in enhancing the efficacy and safety of therapeutic treatments.
